Atallah, E. L., Visotcky, A., Flynn, K. E., Zhang, M.-J., Radich, J. P., Yang, J., … Cortes, J. E. (2022). Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study. In Blood (Vol. 140, pp. 3885–3886). American Society of Hematology. https://doi.org/10.1182/blood-2022-160172

Atallah, Ehab L., Alexis Visotcky, Kathryn E. Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, et al. “Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study.” In Blood, 140:3885–86. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-160172.

Atallah EL, Visotcky A, Flynn KE, Zhang M-J, Radich JP, Yang J, et al. Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study. In: Blood. American Society of Hematology; 2022. p. 3885–6.

Atallah, Ehab L., et al. “Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 3885–86. Crossref, doi:10.1182/blood-2022-160172.

Atallah EL, Visotcky A, Flynn KE, Zhang M-J, Radich JP, Yang J, Oehler VG, Tantravahi SK, Smith BDD, Pinilla Ibarz J, Sweet K, Mauro M, Druker BJ, Thompson JE, Maldonado-Schmidt S, Baim A, Schiffer CA, Kota VK, Cortes JE. Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study. Blood. American Society of Hematology; 2022. p. 3885–3886.